Amlodipine Validation Stability HPLC Combination tablet a b s t r a c t A simple, rapid, accurate, precise and robust HPLC method was developed for the simultaneous determination of fimasartan and amlodipine in tablet dosage form. Furthermore, stability of active ingredients was evaluated under normal and stress conditions. The isocratic elution was accomplished by Nucleosil C18 column (250 mm Â 4.6 mm, 5 mm) at 40 C. The mobile phase consisted of acetonitrile and 0.02 M monopotassium phosphate buffer (pH 2.2) in the ratio of 50:50 (v/v) was eluted at 1.0 ml/min. The eluent was monitored by the UV detector for fimasartan and amlodipine at 237 nm for 8 min, detection time. The validation of HPLC method was carried out in accordance with the ICH guidelines.
1.
Introduction Hypertension is the most common primary cause of cardiovascular morbidities [1] . Multiple-drug therapy is frequently prescribed in the treatment of hypertension [2] . Fimasartan ( Fig. 1A) (2-n-butyl-5-dimethylamino-thiocarbonylmethyl-6methyl-3, pyrimidin-4(3H)) is a newly developed angiotensin II type 1 (AT 1 ) receptor blocker [3] . Its safety and efficacy is well characterized [4] . The Korean Food and Drug Administration (KFDA) has approved fimasartan as a drug in September 2010 [5] . Fimasartan is tolerable when used concomitantly with hydrochlorothiazide, digoxin or amlodipine [6e9]. Amlodipine besylate ( Fig. 1B) (2-[(2-aminoethoxy)-methyl]-4-(2-chlorophenyl) 1, 4-dihydro-6-methyl-3,5-pyridine-dicarboxylic acid-3 ethyl-5 methyl ester) is a calcium channel blocker used in the management of hypertension and angina [10] . A lot of methods have been reported for the determination of amlodipine alone or in combination with other active pharmaceutical agents in dosage forms or in biological fluids [11] . However, simultaneous determination of fimasartan and amlodipine has not been described previously. The purpose of present study was to develop and validate an HPLC method for simultaneous determination of fimasartan and amlodipine in tablet dosage form. Moreover, stability of active ingredients was also evaluated by using this method.
2.
Materials and methods
Materials
Fimasartan and amlodipine drug powders (as reference standards) were obtained from Boryung Pharm. 
Instrumentation and chromatographic conditions
The isocratic elution was carried out using an HPLC system ( 
Preparation of standard concentrations

Stock solutions
The powdered tablets and the tablet powders equivalent to 10 mg fimasartan or amlodipine were weighed and transferred to 100 ml measuring flask. These powdered tablets were weighed after milling the tablet with pestle and mortar. Each sample was dissolved in 100 ml acetonitrile to get the stock solution with final strength of 100 mg/ml. Then, each stock solution was filtered (0.45 mm) before further use.
Calibration standards
Six standard concentrations with 6, 12, 18, 24, 30 and 36 mg/ml were prepared from the stock solution of fimasartan drug powder (pure form). Similarly, six standard strengths with 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mg/ml were prepared from the stock solution of amlodipine drug powder (pure form).
Sample solutions
The standard concentrations with 10, 15 and 30 mg/ml were derived from the stock solution of fimasartan prepared with the powdered tablets. Similarly, standard strengths with 0.625, 1.25 and 2.5 mg/ml were obtained from the stock solution of amlodipine prepared with the powdered tablets. 
System suitability
The typical values for evaluating system suitability of a chromatographic procedure include the RSD <1%, tailing factor <2 and theoretical plates >2000 [12] . The determination of system suitability of analytical method was accomplished by assaying six samples of the same strength of fimasartan or amlodipine. The sample concentration of fimsartan and amlodipine used in this analysis was 10 mg/ml and 0.75 mg/ml, respectively. The retention time, peak area, theoretical plates and tailing factor were evaluated for system suitability.
Sensitivity
The limit of detection (LOD) and quantification limit (LOQ) were determined by gradually diluting the sample and analysing by the proposed method. The signal/noise ratio (S/N) was determined for each tested strength. The typical S/N ratio recommended by the International Conference on Harmonisation (ICH) is 3/1 and 10/1 for LOD and LOQ, respectively [13] .
Calibration curve
The above-mentioned calibration standards were analysed for determining linearity. The sample strengths ranged from 6 to 36 mg/ml and 0.5 to 3.0 mg/ml for fimasartan and amlodipine, respectively. The regression analysis was accomplished by slope, intercept and correlation coefficient (r 2 ).
Accuracy and precision
The accuracy was determined by percent recovery method. Furthermore, precision (inter-day variance and intra-day variance) were determined by assaying samples over a period of 1 day and 3 days, respectively. The standard concentrations of fimasartan used in this investigation were 10, 15 and 30 mg/ml. And, the standard strengths of amlodipine used in this study were 0.625, 1.25 and 2.5 mg/ml.
Robustness
The influence of slight deliberate changes in chromatographic conditions such as column temperature, flow rate of mobile phase and pH of mobile phase on the retention time and peak area were observed one by one. The test was performed in triplicate for each set of conditions. The standard concentrations of fimasartan and amlodipine used in this analysis were 30 mg/ml and 2.5 mg/ml, respectively.
Stability
Stability in sample solutions
The stability of fimasartan and amlodipine in acetonitrile was determined by assaying the selected standard concentrations of these drugs at 1, 2, 4, 8, 16, 32 and 64 h. The standard concentrations of fimasartan and amlodipine used in this study were 30 mg/ml and 2.5 mg/ml, respectively. The samples placed in the auto-sampler at room temperature were assayed and peak areas were recorded.
Stability of powdered tablets under stressed conditions
The stability study of fimasartan and amlodipine in powdered tablets placed under stress environment of temperature, relative humidity and UV radiations was assessed by % assay up to 56 days. 3.
Results and discussion
Hypertension, a chief risk factor for coronary heart disease can be reduced by proper control of blood pressure. Fimasartan (Fig. 1A) could reduce blood pressure by inhibiting the binding of angiotensin II to the angiotensin I receptor in the vascular smooth muscle, and blocking the vasoconstriction and aldosterone-secreting effects of angiotension II [10] . Amlodipine (Fig. 1B) , a derivative of dihydropyridines, blocks the calcium influx into vascular smooth muscle and cardiac muscle, leading to decrease in peripheral vascular resistance [6e9]. The combination therapy with fimasartan and amlodipine can provide synergistic effects to the hypertensive patients, since they give different mechanisms of antihypertensive action [3, 7] . Several methods have been reported for simultaneous determination of amlodipine with other drugs [11] . However, chromatographic determination of amlodipine with fimasartan has not been addressed previously. Accordingly, in present research simultaneous determination of fimasartan and amlodipine in tablet dosage form was developed and validated. Furthermore, stability of active ingredients was determined in samples stored under normal and accelerated conditions using the described method. In this HPLC method acetonitrile and 0.02 M monopotassium phosphate buffer (50/ 50, v/v) were used as mobile phase. The chromatogram containing peaks of fimasartan and amlodipine in 8 min detection time is shown in Fig. 2 . The selected chromatographic conditions resulted in retention of fimasartan and amlodipine at 5.24 AE 0.03 and 2.64 AE 0.08 min (n ¼ 6), respectively (Fig. 2) . The applied analytical conditions produced the peaks with suitable peak symmetry (<2) [12] . The typical conditions for system suitability of an analytical method encompass the relative standard deviation (RSD) < 1%, peak symmetry <2 and theoretical plates >2000 [12] . The results of system suitability of present chromatographic method 6) .
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are described in Table 1 . The peak area, retention time, tailing factor and theoretical plates were within the recommended limits. Therefore, the method was considered as suitable. The standard S/N ratio for LOD and LOQ in accordance with the ICH guidelines is 3/1 and 10/1, respectively [13] . For fimasartan, the present HPLC method provided S/N ratio (mean AE S.D., n ¼ 3) of 3.212 AE 0.109 and 10.521 AE 0.532 corresponding to 3.5 mg/ml and 15 mg/ml, respectively. Thus, these were regarded as LOD and LOQ of fimasartan, respectively. Likewise, the standard concentrations of amlodipine with 0.35 mg/ml and 1.0 mg/ml furnished S/N ratio of 3.042 AE 0.097 and 10.331 AE 0.451 (mean AE S.D., n ¼ 3), respectively. Therefore, they were designated as LOD and LOQ of amlodipine, respectively.
Each calibration curve was constructed with six standard strengths (Fig. 3) . The calibration curve of fimasartan was made with 6, 12, 18, 24, 30 and 36 mg/ml concentrations (Fig. 3A) . Similarly, the concentrations used in the formation of calibration curve of amlodipine were 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mg/ml (Fig. 3B) . The regression analysis is displayed in Table 2 . The correlation coefficient (r 2 ) was 0.9997 and 0.9999 for fimasartan and amlodipine, respectively.
The results of accuracy and precision (inter-day variance and intra-day variance) are shown in Table 3 . For accuracy, all the recovery values were within AE5%. The mean recovery value of fimasartan and amlodipine was 99.12% and 99.44%, respectively. For inter-day and intra-day variance assessment %RSD was calculated. All the samples exhibited RSD values <1% confirming that the analytical method was precise [12] . Table 4 reveals the results of minor modifications in analytical conditions such as temperature of column, flow rate of mobile phase and pH of mobile phase. No substantial variances were observed in the retention time and peak area of each component when the chromatographic conditions were slightly changed one by one. Moreover, the RSD for each value was <1%. Thus, the proposed method was considered as robust. a s i a n j o u r n a l o f p h a r m a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1 2 3 e1 2 8
The stability evaluation of fimasartan and amlodipine in sample solutions (constituted with acetonitrile) was performed up to 64 h. The sample solutions placed in the autosampler at room temperature were analysed periodically at 1, 2, 4, 8, 16, 32 and 64 h. The results are shown in Table 5 . The peak areas of each drug were not considerably different from each other. Moreover, RSD value of each sample was <1%. The slight increase in peak area with the passage of time suggested that small evaporation of the solvent took place resulting in increased concentration of the sample. According to our results the drugs dissolved in acetonitrile were stable at room temperature during analysis over a period of 64 h.
The stability study of fimasartan and amlodipine in powdered tablet samples placed under ambient conditions of temperature, relative humidity and UV radiations was carried out up to 56 days. The powdered tablet samples were separately stored at room temperature (R.T.), 45 C, 60 C, 40 C with 75% relative humidity (RH) and ultraviolet radiations (UV) for investigating the influence of these conditions on fimasartan and amlodipine. The assay (%) of fimasartan and amlodipine in each sample was determined and recorded prior to exposure to these conditions. Then, the labelled samples were stored under the above-mentioned conditions. Each sample was assayed periodically for fimasartan and amlodipine. The results of fimasartan and amlodipine content (% assay) at 14, 28, 42 and 56 day are shown in Table 6 . All the values are within the 95e105%. Thus, fimasartan and amlodipine were stable in combination tablet dosage form under intentionally applied stressed conditions.
Conclusions
The present HPLC method for simultaneous determination of fimasartan and amlodipine proved to be simple, rapid, precise, accurate and robust. Moreover, fimasartan and amlodipine were found stable in the sample solutions placed at room temperature up to 64 h. Furthermore, the drugs in the powdered tablet samples exposed to applied conditions were also found stable over a period 56 days. Accordingly, the proposed analytical procedure with detection time of 8 min can be used for reliable simultaneous determination of fimasartan and amlodipine in pure and tablet dosage form.
